Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 4/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | SCN1A | P35498 | 4/20 | 0.47 |
| ▸ | SCN8A | Q9UQD0 | 4/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.47 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.44 |
| ▸ | CCR2 | P41597 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4008352 | 0.94 | ROCK1 (0.63) | ROCK1KCNH2ROCK2SMN1; SMN2SCN1A | |
| SCHEMBL4008346 | 0.94 | ROCK1 (0.63) | ROCK1KCNH2ROCK2SMN1; SMN2SCN1A | |
| SCHEMBL4008587 | 0.94 | ROCK1 (0.63) | ROCK1KCNH2ROCK2SMN1; SMN2SCN1A | |
| SCHEMBL4007568 | 0.92 | ROCK1 (0.58) | ROCK1KCNH2ROCK2SCN1ASCN8A | |
| SCHEMBL4008300 | 0.91 | ROCK1 (0.57) | ROCK1KCNH2ROCK2SCN1ASCN8A | |
| SCHEMBL4006367 | 0.88 | ROCK1 (0.72) | ROCK1KCNH2ROCK2SCN1ASCN8A | |
| SCHEMBL4010045 | 0.82 | ROCK1 (0.45) | ROCK1KCNH2ROCK2SMN1; SMN2MAOA | |
| SCHEMBL4008293 | 0.82 | ROCK1 (1.00) | ROCK1KCNH2ROCK2SMN1; SMN2CCR2 | |
| SCHEMBL4010766 | 0.81 | ROCK1 (0.61) | ROCK1KCNH2ROCK2MCHR1CCR2 | |
| SCHEMBL12193416 | 0.80 | ROCK1 (0.53) | ROCK1ROCK2SMN1; SMN2SCN1ASCN8A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963304-B2 | ISOQUINOLINE DERIVATIVES | MSD OSS BV (NL) | 2015-05-13 | — | — | EP | disclosed |
| US-7618985-B2 | Isoquinoline derivatives | N.V. ORGANON (NL) | 2009-11-17 | — | — | US | disclosed |
| EP-1963304-B1 | ISOQUINOLINE DERIVATIVES | ORGANON NV (NL) | 2009-06-24 | — | — | EP | disclosed |
| EP-1963304-A1 | ISOQUINOLINE DERIVATIVES | N.V. Organon (NL) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007065916-A1 | ISOQUINOLINE DERIVATIVES | N.V. ORGANON (NL) | 2007-06-14 | — | — | WO | disclosed |
| US-20070135479-A1 | Isoquinoline derivatives | N.V. ORGANON (NL) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135479-A1 | Isoquinoline derivatives | ROCK1, ROCK2, RHOA | ROCK1 1/4885KCNH2 343/4885ROCK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.